The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 22, 2012
Filed:
Jan. 26, 2010
Zhaoning Zhu, Plainsboro, NJ (US);
Zhong-yue Sun, Parlin, NJ (US);
Andrew Stamford, Chatham Township, NJ (US);
William J. Greenlee, Teaneck, NJ (US);
Jared N. Cumming, Garwood, NJ (US);
Lingyan Wang, East Brunswick, NJ (US);
Ulrich Iserloh, Hoboken, NJ (US);
Xiaoxiang Liu, River Vale, NJ (US);
Ying Huang, Berkeley Heights, NJ (US);
Guoqing LI, Belle Mead, NJ (US);
Jianping Pan, Monmouth Junction, NJ (US);
Zhaoning Zhu, Plainsboro, NJ (US);
Zhong-Yue Sun, Parlin, NJ (US);
Andrew Stamford, Chatham Township, NJ (US);
William J. Greenlee, Teaneck, NJ (US);
Jared N. Cumming, Garwood, NJ (US);
Lingyan Wang, East Brunswick, NJ (US);
Ulrich Iserloh, Hoboken, NJ (US);
Xiaoxiang Liu, River Vale, NJ (US);
Ying Huang, Berkeley Heights, NJ (US);
Guoqing Li, Belle Mead, NJ (US);
Jianping Pan, Monmouth Junction, NJ (US);
Schering Corporation, Kenilworth, NJ (US);
Pharmacopeia Inc., La Jolla, CA (US);
Abstract
Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic magonist or mantagonist.